Caris Life Sciences (CAI) Preferred Stock Liabilities (2024 - 2025)
Caris Life Sciences' (CAI) quarterly Preferred Stock Liabilities came in at $2.2 billion in Q1 2025, up 1.1% quarter-over-quarter from $2.2 billion in Q4 2024.
Caris Life Sciences (CAI) Preferred Stock Liabilities (2024 - 2025) Analysis & Trends
Caris Life Sciences' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $2.2 billion for Q1 2025.
- On a quarterly basis, Preferred Stock Liabilities changed N/A year-over-year to $2.2 billion in Q1 2025; TTM through Mar 2025 was $2.2 billion, a N/A change from a year earlier, with the FY2024 full-year figure at $2.2 billion, up 4.53% from the prior year.
- Preferred Stock Liabilities advanced to $2.2 billion in Q1 2025 per CAI's latest filing, from $2.2 billion in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $2.2 billion in Q1 2025 and bottomed at $2.2 billion in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Caris Life Sciences | 4.42 Bn | 3.60 Bn | 214.23 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 2.25 Bn |
| Dec 31, 2024 | 2.22 Bn |
| Sep 30, 2024 | 2.20 Bn |
| Jun 30, 2024 | 2.17 Bn |